Welcome to our dedicated page for ZEAL news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on ZEAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZEAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZEAL's position in the market.
Zealand Pharma (Nasdaq: ZEAL) announced transactions involving its shares by managerial personnel and their close associates as of September 7, 2021. This disclosure aligns with regulatory requirements for transparency regarding insider trading. Zealand Pharma is a biotechnology company specializing in peptide-based medicines and has successfully marketed two products, V-Go® and Zegalogue®. The company is supported by collaborations with Boehringer Ingelheim and AstraZeneca, enhancing its market presence.
Zealand Pharma (Nasdaq: ZEAL) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021. Members of the senior management team will present at 10:15 a.m. ET (4:15 p.m. CET). A live webcast will be available on the company's website, with a replay archived post-presentation. Zealand focuses on innovative peptide-based medicines, with products like V-Go® and Zegalogue® on the market, and several candidates in clinical development.
Zealand Pharma (Nasdaq: ZEAL) announced transactions involving its shares conducted by persons in managerial positions as of September 2, 2021. The biotechnology company focuses on peptide-based medicines, with over 10 drug candidates advancing in clinical development, including V-Go® and Zegalogue®. These developments are supported by its dedicated sales force in the U.S. and collaborations with Boehringer Ingelheim and AstraZeneca.
For further details, please check the attached files.
Zealand Pharma A/S has appointed Anneline Nansen as an employee-elected director on its Board of Directors, effective September 1, 2021. Nansen, previously an alternate representative since 2020, replaces Gertrud Koefoed Rasmussen, who resigned. Zealand, traded on Nasdaq under the symbol ZEAL, is a biotechnology firm specializing in peptide-based medicines, with two products currently on the market and several in clinical development. The company aims to enhance patient care through its innovative treatments for diabetes and severe hypoglycemia.
Zealand Pharma announces its participation in the Goldman Sachs 11th Annual Biotech Symposium on September 7, 2021. The event will feature members of Zealand's senior management team discussing the company’s advancements in peptide-based medicines. Zealand Pharma has successfully brought V-Go® and Zegalogue® to market and continues to develop additional drug candidates. With a strong presence in both Copenhagen and the U.S., the company is positioned for further growth and collaboration.
Zealand Pharma announced its share capital update as of August 31, 2021, reporting a total of 43,550,949 shares with corresponding voting rights. This follows the exercise of employee warrants, as outlined in previous communications. Zealand, listed on NASDAQ: ZEAL, focuses on peptide-based medicines and has two marketed products, V-Go® and Zegalogue®. The company continues to expand its clinical pipeline and has collaborations with Boehringer Ingelheim and AstraZeneca.
Zealand Pharma has raised its share capital by DKK 9,111 through the exercise of employee warrants. A total of 9,111 new shares will be issued, with exercise prices set at DKK 135.30 and DKK 100.80 for different shares. This capital increase generates proceeds of DKK 982,351.80, contributing to a new total share capital of DKK 43,550,949. The new shares will have voting rights and dividend entitlements from the date of exercise. The increased capital reflects Zealand Pharma’s commitment to incentivizing employees and supporting its growth strategy.
Zealand Pharma announced the first patient has been dosed in the EASE-SBS 4 Phase 3b trial evaluating glepaglutide for patients with short bowel syndrome (SBS). This trial aims to assess the long-term effects of glepaglutide on intestinal absorption, with 10 patients receiving once-weekly injections over 26 weeks. The pivotal EASE-SBS 1 trial remains on track for results in 2022. Glepaglutide is designed to reduce parenteral support needs for SBS patients, enhancing their nutritional goals.
Zealand Pharma A/S (Nasdaq: ZEAL) announces the resignation of Gertrude Koefoed Rasmussen, an employee-elected member of its Board, effective August 31, 2021. She will leave the company to pursue another employment opportunity. Zealand Pharma is a biotechnology firm focused on developing peptide-based medicines for metabolic and gastrointestinal diseases, with a promising pipeline that includes multiple candidates in clinical stages. The company was founded in 1998 and has a significant presence in the U.S.
On August 12, 2021, Zealand Pharma A/S (Nasdaq: ZEAL) announced its H1 2021 financial results, reporting revenue of DKK 132.1 million, a decrease from DKK 233.4 million in H1 2020. Net operating expenses rose to DKK 616.6 million from DKK 437.2 million. The company launched ZEGALOGUE® (dasiglucagon) in the U.S., aimed at treating severe hypoglycemia in diabetes patients. Zealand Pharma's cash reserves stood at DKK 1,282.9 million. Despite declines in revenue and increased expenses, the company is focused on expanding its pipeline with multiple clinical trials and aims to introduce five marketed products by 2025.
